BioCardia, Inc. Notified by Nasdaq of Minimum Bid Price Non‑Compliance

What Happened
BioCardia, Inc. announced in an 8-K (filed August 21, 2026) that Nasdaq’s Listing Qualifications staff sent a notice saying the company’s common stock has traded below the $1.00 per‑share minimum under Nasdaq Listing Rule 5550(a)(2) for the last 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), BioCardia has an initial 180‑calendar‑day cure period — until February 16, 2027 — to regain compliance. Nasdaq will consider the company compliant if the closing bid is at least $1.00 for ten consecutive business days. The notice does not affect current listing or trading.

Key Details

• Nasdaq notice triggered by at least 30 consecutive business days with shares below $1.00.
• Initial compliance period: 180 calendar days, ending February 16, 2027.
• Compliance standard: closing bid ≥ $1.00 for 10 consecutive business days to be deemed compliant.
• If not cured, BioCardia may be eligible for a second 180‑day period if it meets market‑value‑of‑publicly‑held‑shares and other initial listing standards (except the minimum bid price) and files an intention to cure, which could include a reverse stock split; failure to cure could lead to delisting and an appeal process.

Why It Matters
This notice signals a risk to BioCardia’s Nasdaq listing if the company’s share price does not recover. While trading is not suspended now, prolonged noncompliance could lead to delisting, which can reduce liquidity and make the stock harder to trade. The company may pursue options (for example, a reverse stock split) to regain compliance, but the 8‑K emphasizes there is no assurance compliance will be achieved or extended. Investors should monitor the company’s closing share price, company announcements about remedial actions, and subsequent SEC filings for updates.